This author has not written his bio yet.
But we are proud to say that Ilona Margolis contributed 22 entries already.
Dallas, TX – December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D., as its Chief Medical Officer (CMO). “We are excited that Dr. Raj will continue driving clinical efforts with our leadership team as […]
Sydney, Australia – November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia. ERX-315 is Etira’s first-in-class small molecule drug designed to selectively induce catastrophic endoplasmic reticulum stress in […]
Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath, MD, PhD to its Board of Directors. The new board members bring a strong blend of clinical, technical, and commercial experience and expertise. […]
Seattle, WA – September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th Biennial Ovarian Cancer Research Symposium. The data establishes that ER stress in ovarian cancer (OCa) is […]
Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney Australia for the ERX-315-001 Phase 1 clinical trial. The study related protocol, procedures, processes, monitoring plan and study logistics […]
Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled “A Phase 1 Trial of ERX-315 in Participants with Advanced Solid Tumors” The trial will begin […]
Melbourne, Australia – July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities for innovation across medicine formulation, resolving manufacturing process challenges and building supply of highly-skilled, industry ready candidates for the workforce. MMIC […]
Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein, the design of oligo-benzamides, efficient synthetic routes and preclinical studies showing their activity are detailed. Etira’s therapeutic compounds are based on […]
Dallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This submission marks a significant milestone for EtiraRx and approval by HREC will enable the start of phase 1 […]
San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity is dependent on LIPA expression. The data support the advancement of ERX-208 towards clinical trials in ovarian cancer.
Boston Office:
75 Kneeland Ave, 14th Floor
Boston. MA. 02111
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247